Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors.

Hajósi-Kalcakosz S, Dezső K, Bugyik E, Bödör C, Paku S, Pávai Z, Halász J, Schlachter K, Schaff Z, Nagy P.

Diagn Pathol. 2012 Jul 18;7:86. doi: 10.1186/1746-1596-7-86.

2.

EZH2 is a sensitive marker of malignancy in salivary gland tumors.

Hajósi-Kalcakosz S, Vincze E, Dezső K, Paku S, Rókusz A, Sápi Z, Tóth E, Nagy P.

Diagn Pathol. 2015 Sep 17;10:163. doi: 10.1186/s13000-015-0392-z.

3.

EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.

Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D.

Gut. 2011 Jul;60(7):967-76. doi: 10.1136/gut.2010.231993. Epub 2011 Feb 17.

PMID:
21330577
4.

Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.

Sasaki M, Matsubara T, Kakuda Y, Sato Y, Nakanuma Y.

Am J Surg Pathol. 2014 Mar;38(3):364-9. doi: 10.1097/PAS.0000000000000125.

PMID:
24487593
5.

EZH2, a unique marker of malignancy in effusion cytology.

Jiang H, Gupta R, Somma J.

Diagn Cytopathol. 2014 Feb;42(2):111-6. doi: 10.1002/dc.22999. Epub 2013 May 2.

PMID:
23636867
6.

The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.

Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, Minato H, Ohta T, Nakanuma Y.

Lab Invest. 2008 Aug;88(8):873-82. doi: 10.1038/labinvest.2008.52. Epub 2008 Jun 30.

7.

Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.

Lee H, Yoon SO, Jeong WY, Kim HK, Kim A, Kim BH.

Hum Pathol. 2012 Oct;43(10):1704-10. doi: 10.1016/j.humpath.2011.12.019. Epub 2012 Apr 18.

PMID:
22520951
8.

Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics.

Wan L, Li X, Shen H, Bai X.

Clin Transl Oncol. 2013 Feb;15(2):132-8. doi: 10.1007/s12094-012-0897-9. Epub 2012 Jul 24.

PMID:
22855181
9.

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.

Guo S, Li X, Rohr J, Wang Y, Ma S, Chen P, Wang Z.

Diagn Pathol. 2016 Apr 26;11:41. doi: 10.1186/s13000-016-0491-5.

10.

Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.

Xu B, Abourbih S, Sircar K, Kassouf W, Mansure JJ, Aprikian A, Tanguay S, Brimo F.

Arch Pathol Lab Med. 2013 Oct;137(10):1326-36. doi: 10.5858/arpa.2012-0525-OA. Review.

PMID:
24079759
11.

Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor.

Kampilafkos P, Melachrinou M, Kefalopoulou Z, Lakoumentas J, Sotiropoulou-Bonikou G.

Am J Dermatopathol. 2015 Feb;37(2):138-44. doi: 10.1097/DAD.0b013e31828a2d54.

PMID:
25614949
12.

EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.

Kuroki H, Hayashi H, Okabe H, Hashimoto D, Takamori H, Nakahara O, Nakagawa S, Fukushima Y, Chikamoto A, Beppu T, Hirota M, Iyama K, Baba H.

PLoS One. 2014 Aug 1;9(8):e100904. doi: 10.1371/journal.pone.0100904. eCollection 2014.

13.

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.

Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H.

Cancer. 2010 Jun 15;116(12):3015-24. doi: 10.1002/cncr.25128.

14.

Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.

Yonemitsu Y, Imazeki F, Chiba T, Fukai K, Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, Iwama A, Yokosuka O.

Hum Pathol. 2009 Sep;40(9):1304-11. doi: 10.1016/j.humpath.2009.01.017. Epub 2009 Apr 22.

PMID:
19386347
16.

High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.

Findeis-Hosey JJ, Huang J, Li F, Yang Q, McMahon LA, Xu H.

Hum Pathol. 2011 Jun;42(6):867-72. doi: 10.1016/j.humpath.2010.09.019. Epub 2011 Feb 2.

PMID:
21292308
17.

Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.

Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE.

Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):170-6. doi: 10.1097/PAI.0b013e31825d527f.

PMID:
22914605
18.

Cellular senescence in biliary pathology. Special emphasis on expression of a polycomb group protein EZH2 and a senescent marker p16INK4a in bile ductular tumors and lesions.

Sasaki M, Nakanuma Y.

Histol Histopathol. 2015 Mar;30(3):267-75. doi: 10.14670/HH-30.267. Epub 2014 Oct 7. Review.

PMID:
25289642
19.

Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins.

Venneti S, Le P, Martinez D, Xie SX, Sullivan LM, Rorke-Adams LB, Pawel B, Judkins AR.

Am J Surg Pathol. 2011 Oct;35(10):1463-72. doi: 10.1097/PAS.0b013e318224d2cd.

PMID:
21921784
20.

MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.

Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, Lu M, Cicinnati VR.

J Hepatol. 2014 Mar;60(3):590-8. doi: 10.1016/j.jhep.2013.10.028. Epub 2013 Nov 6.

PMID:
24211739

Supplemental Content

Support Center